Off-label medicine use Ethics, practice and future directions

被引:2
|
作者
Bell, J. Simon [1 ]
Richards, Georgia C. [2 ]
机构
[1] Monash Univ, Fac Pharm & Pharmaceut Sci, Ctr Med Use & Safety, Clayton, Vic, Australia
[2] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Ctr Evidence Based Med, Radcliffe Observ Quarter, Woodstock Rd, Oxford, England
关键词
CHILDREN;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Medicine use is considered off-label when used for an indication, at a dose, via a route of administration or in a patient group not included in the approved product information. Off-label use varies according to therapeutic class and patient group, and often occurs in those who are vulnerable. Objective The aim of this article is to discuss ethical, practice and policy considerations associated with off-label medicine use. Discussion A number of professional organisations have issued guidance in relation to off-label medicine use. Prescribers should inform patients and document consent when prescribing off-label, including an open discussion about known and unknown benefits and risks. It is important that the prescriber documents the reason for off-label use in the patient's record and ensures that patients are aware of the intended duration and relevant monitoring. Australia's new national health priority of Quality Use of Medicine and Medicine Safety should stimulate all stakeholders including consumers to work together to address off-label medicine use.
引用
收藏
页码:329 / 331
页数:3
相关论文
共 50 条
  • [1] Off-label use in palliative medicine
    Remi, Constanze
    Gerlach, Christina
    [J]. ONKOLOGE, 2021, 27 (11): : 1137 - 1150
  • [2] Off-label use in palliative medicine
    Remi, Constanze
    Gerlach, Christina
    [J]. SCHMERZ, 2021, 35 (01): : 61 - 73
  • [3] Oral medicine: Off-label cream use
    S. Porter
    V. Mercadante
    S. Fedele
    [J]. British Dental Journal, 2014, 217 : 660 - 661
  • [4] ORAL MEDICINE Off-label cream use
    Porter, S.
    Mercadante, V.
    Fedele, S.
    [J]. BRITISH DENTAL JOURNAL, 2014, 217 (12) : 660 - 661
  • [5] Omalizumab for Asthma: Indications, Off-Label Uses and Future Directions
    Ben-Shoshan, Moshe
    [J]. RECENT PATENTS ON INFLAMMATION & ALLERGY DRUG DISCOVERY, 2010, 4 (03) : 183 - 192
  • [6] Off-label use of maraviroc in clinical practice
    Blanco, Jose-Ramon
    Ochoa-Callejero, Laura
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2016, 14 (01) : 5 - 8
  • [7] Ethics of off-label treatment
    Atkins, CD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) : 1637 - 1637
  • [8] Off-label use of antipsychotics: Rethinking "off-label"
    Groleger, Urban
    [J]. PSYCHIATRIA DANUBINA, 2007, 19 (04) : 350 - 353
  • [9] 'Off-label' drug use in sexual medicine treatment
    Fallon, B.
    [J]. INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2008, 20 (02) : 127 - 134
  • [10] HUNGARIAN EXPERIENCES IN THE AUTHORISATION OF OFF-LABEL MEDICINE USE
    Bodi, B.
    Bicsak, A.
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 42 - 43